TCGA-F7-A50G-01A-11R-A266-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.470
- BILE_ACID_METABOLISM+0.350
- ALLOGRAFT_REJECTION+0.320
- KRAS_SIGNALING_DN+0.320
- COAGULATION+0.280
- P53_PATHWAY+0.230
- PANCREAS_BETA_CELLS+0.220
- XENOBIOTIC_METABOLISM+0.220
- COMPLEMENT+0.210
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.530
- MYC_TARGETS_V1-0.490
- OXIDATIVE_PHOSPHORYLATION-0.460
- G2M_CHECKPOINT-0.440
- MTORC1_SIGNALING-0.350
- MITOTIC_SPINDLE-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- ADIPOGENESIS-0.250
- DNA_REPAIR-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-69-8254-01A-11R-2287-07 | — | cohortA1 | 0.889 |
| 2 | 855f0a82-04de-485d-9613-5ccf08074069 | — | — | 0.886 |
| 3 | BS_KN92S7YQ | Med | Medulloblastoma | 0.873 |
| 4 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.872 |
| 5 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.868 |
| 6 | MDT-AP-2888 | Med | Medulloblastoma | 0.866 |
| 7 | ERR2208952 | — | — | 0.857 |
| 8 | BS_0WVJYM9R | pilocytic astrocytoma | — | 0.855 |
| 9 | TCGA-69-8453-01A-12R-2326-07 | — | cohortA1 | 0.853 |
| 10 | BS_NYS8TRCB | low-grade glioma | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |